相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real-world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia
Maria Teresa Voso et al.
EUROPEAN JOURNAL OF HAEMATOLOGY (2016)
International phase 3 study of azacitidine vs conventional care regimens in older patients with newly diagnosed AML with >30% blasts
Herve Dombret et al.
BLOOD (2015)
Overexpression of GYS1, MIF, and MYC Is Associated With Adverse Outcome and Poor Response to Azacitidine in Myelodysplastic Syndromes and Acute Myeloid Leukemia
Jose F. Falantes et al.
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA (2015)
Digging deep into dirty'' drugs - modulation of the methylation machinery
Lisa Pleyer et al.
DRUG METABOLISM REVIEWS (2015)
Effectiveness of azacitidine in unselected high-risk myelodysplastic syndromes: results from the Spanish registry
T. Bernal et al.
LEUKEMIA (2015)
Azacitidine frontline therapy for unfit acute myeloid leukemia patients: Clinical use and outcome prediction
F. Ramos et al.
LEUKEMIA RESEARCH (2015)
BCL2L10 is a predictive factor for resistance to Azacitidine in MDS and AML patients
Thomas Cluzeau et al.
Oncotarget (2015)
Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network
Pierre Bories et al.
AMERICAN JOURNAL OF HEMATOLOGY (2014)
Azacitidine in 302 patients with WHO-defined acute myeloid leukemia: results from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer et al.
ANNALS OF HEMATOLOGY (2014)
Myelodysplastic syndromes: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
P. Fenaux et al.
ANNALS OF ONCOLOGY (2014)
Bone marrow hypocellularity does not affect tolerance or efficacy of azacitidine in patients with higher-risk myelodysplastic syndromes
John F. Seymour et al.
BRITISH JOURNAL OF HAEMATOLOGY (2014)
Absence of aberrant myeloid progenitors by flow cytometry is associated with favorable response to azacitidine in higher risk myelodysplastic syndromes
Canan Alhan et al.
CYTOMETRY PART B-CLINICAL CYTOMETRY (2014)
Novel therapeutic strategies using hypomethylating agents in the treatment of myelodysplastic syndrome
Takayuki Ishikawa
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY (2014)
Azacitidine induces profound genome-wide hypomethylation in primary myelodysplastic bone marrow cultures but may also reduce histone acetylation
M. Grovdal et al.
LEUKEMIA (2014)
Expression of nucleoside-metabolizing enzymes in myelodysplastic syndromes and modulation of response to azacitidine
A. Valencia et al.
LEUKEMIA (2014)
Challenges of phase III trial design for novel treatments in diseases with no standard treatment: The AZA-001 myelodysplasia study model
Pierre Fenaux et al.
LEUKEMIA RESEARCH (2014)
Azacitidine in CMML: Matched-pair analyses of daily-life patients reveal modest effects on clinical course and survival
Lisa Pleyer et al.
LEUKEMIA RESEARCH (2014)
Minimizing risk of hypomethylating agent failure in patients with higher-risk MDS and practical management recommendations
Valeria Santini et al.
LEUKEMIA RESEARCH (2014)
A Phase I Study in Patients with Solid or Hematologic Malignancies of the Dose Proportionality of Subcutaneous Azacitidine and Its Pharmacokinetics in Patients with Severe Renal Impairment
Eric Laille et al.
PHARMACOTHERAPY (2014)
Treating acute myeloid leukemia in older adults
Eunice S. Wang
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
Survival and hospitalization among patients with acute myeloid leukemia treated with azacitidine or decitabine in a large managed care population: a real-world, retrospective, claims-based, comparative analysis (Vol 3, 19, 2014)
B. Douglas Smith et al.
EXPERIMENTAL HEMATOLOGY & ONCOLOGY (2014)
Monosomal karyotype improves IPSS-R stratification in MDS and AML patients treated with Azacitidine
Thomas Cluzeau et al.
AMERICAN JOURNAL OF HEMATOLOGY (2013)
Prognostic impact of the number of methylated genes in myelodysplastic syndromes and acute myeloid leukemias treated with azacytidine
Maria Abaigar et al.
ANNALS OF HEMATOLOGY (2013)
A multivariate analysis of the relationship between response and survival among patients with higher-risk myelodysplastic syndromes treated within azacitidine or conventional care regimens in the randomized AZA-001 trial
Steven D. Gore et al.
HAEMATOLOGICA (2013)
Azacitidine in patients with WHO-defined AML - Results of 155 patients from the Austrian Azacitidine Registry of the AGMT-Study Group
Lisa Pleyer et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2013)
Safety and efficacy of 5-azacytidine treatment in myelodysplastic syndrome patients with moderate and mild renal impairment
Evdoxia Douvali et al.
LEUKEMIA RESEARCH (2013)
Azacitidine results in comparable outcome in newly diagnosed AML patients with more or less than 30% bone marrow blasts
L. H. van der Helm et al.
LEUKEMIA RESEARCH (2013)
Epigenetic therapy is associated with similar survival compared with intensive chemotherapy in older patients with newly diagnosed acute myeloid leukemia
Alfonso Quintas-Cardama et al.
BLOOD (2012)
Revised International Prognostic Scoring System for Myelodysplastic Syndromes
Peter L. Greenberg et al.
BLOOD (2012)
Azacitidine for the treatment of patients with acute myeloid leukemia
Luca Maurillo et al.
CANCER (2012)
Azacitidine A Review of its Use in the Management of Myelodysplastic Syndromes/Acute Myeloid Leukaemia
Gillian M. Keating
DRUGS (2012)
Application of French prognostic score to patients with International Prognostic Scoring System intermediate-2 or high risk myelodysplastic syndromes treated with 5-azacitidine is able to predict overall survival and rate of response
Massimo Breccia et al.
LEUKEMIA & LYMPHOMA (2012)
Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine
Raphael Itzykson et al.
BLOOD (2011)
Platelet doubling after the first azacitidine cycle is a promising predictor for response in myelodysplastic syndromes (MDS), chronic myelomonocytic leukaemia (CMML) and acute myeloid leukaemia (AML) patients in the Dutch azacitidine compassionate named patient programme
Lieke H. van der Helm et al.
BRITISH JOURNAL OF HAEMATOLOGY (2011)
Continued Azacitidine Therapy Beyond Time of First Response Improves Quality of Response in Patients With Higher-Risk Myelodysplastic Syndromes
Lewis R. Silverman et al.
CANCER (2011)
Phase I and II study of azacitidine in Japanese patients with myelodysplastic syndromes
Toshiki Uchida et al.
CANCER SCIENCE (2011)
DNA Methylation Changes Following 5-azacitidine Treatment in Patients with Myelodysplastic Syndrome
Huong Thi Thanh Tran et al.
JOURNAL OF KOREAN MEDICAL SCIENCE (2011)
Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias
R. Itzykson et al.
LEUKEMIA (2011)
Azacytidine and Decitabine Induce Gene-Specific and Non-Random DNA Demethylation in Human Cancer Cell Lines
Sabine Hagemann et al.
PLOS ONE (2011)
Predictive value of pretreatment risk group and baseline LDH levels in MDS patients receiving azacitidine treatment
Joon Ho Moon et al.
ANNALS OF HEMATOLOGY (2010)
Prolonged survival with improved tolerability in higher-risk myelodysplastic syndromes: azacitidine compared with low dose ara-C
Pierre Fenaux et al.
BRITISH JOURNAL OF HAEMATOLOGY (2010)
In vitro assessment of cytochrome P450 inhibition and induction potential of azacitidine
Yong Chen et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2010)
Effects of azacitidine compared with conventional care regimens in elderly (≥75 years) patients with higher-risk myelodysplastic syndromes
John F. Seymour et al.
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY (2010)
A phase I biological study of azacitidine (Vidaza™) to determine the optimal dose to inhibit DNA methylation
Ilan Bernstein et al.
EPIGENETICS (2010)
Azacitidine Prolongs Overall Survival Compared With Conventional Care Regimens in Elderly Patients With Low Bone Marrow Blast Count Acute Myeloid Leukemia
Pierre Fenaux et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Mechanisms of resistance to 5-aza-2′-deoxycytidine in human cancer cell lines
Taichun Qin et al.
BLOOD (2009)
Aberrant DNA methylation is a dominant mechanism in MDS progression to AML
Ying Jiang et al.
BLOOD (2009)
The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes
James W. Vardiman et al.
BLOOD (2009)
MDS and secondary AML display unique patterns and abundance of aberrant DNA methylation
Maria E. Figueroa et al.
BLOOD (2009)
Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study
Pierre Fenaux et al.
LANCET ONCOLOGY (2009)
The DNA methyltransferase inhibitors azacitidine, decitabine and zebularine exert differential effects on cancer gene expression in acute myeloid leukemia cells
C. Flotho et al.
LEUKEMIA (2009)
Reduction of phosphoinositide-phospholipase C beta1 methylation predicts the responsiveness to azacitidine in high-risk MDS
Matilde Y. Follo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2009)
CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine
K. Raj et al.
LEUKEMIA (2007)
Pharmacokinetics of 5-azacitidine administered with phenylbutyrate in patients with refractory solid tumors or hematologic malignancies
MA Rudek et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: A study of the cancer and leukemia group B
LR Silverman et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
分享论文
